Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McClellan, Lasheaka
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis	Recruiting	2	180	Europe, Canada, Japan, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Biliary Cholangitis, PBC	12/25	12/25
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk	Recruiting	N/A	2500	US	Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test	Exact Sciences Corporation	Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer	01/25	04/26
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection	Recruiting	N/A	5000	Canada, US	All approved therapies for the treatment of Chronic Hepatitis B (CHB)	Target PharmaSolutions, Inc.	Hepatitis B, Hepatitis, Liver Diseases	01/26	01/26
Ghali, Maged
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis	Recruiting	2	180	Europe, Canada, Japan, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Biliary Cholangitis, PBC	12/25	12/25